糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展

doi:10.16138/j.1673-6087.2021.06.012

摘要/Abstract

关键词: 糖化血红蛋白变异性, 糖尿病微血管并发症, 糖尿病视网膜病变, 糖尿病肾病, 糖尿病神经病变

中图分类号:

R587

缪雅, 杨玉琳, 朱怡洁, 盛长生, 田景琰. 糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展[J]. 内科理论与实践, 2021, 16(06): 427-430.

参考文献 36

[1]	Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association[J]. BMJ, 2020, 369: m997.
[2]	Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843 URL
[3]	Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA_1c variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes[J]. Diabetes Care, 2020, 43(2): 426-432. doi: 10.2337/dc19-0823 URL
[4]	Virk SA, Donaghue KC, Cho YH, et al. Association between HbA_1c variability and risk of microvascular com-plications in adolescents with type 1 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(9): 3257-3263. doi: 10.1210/jc.2015-3604 URL
[5]	Iuchi H, Sakamoto M, Matsutani D, et al. The durability of basal insulin affects day-to-day glycemic variability assessed by continuous glucose monitoring in type 2 diabetes patients[J]. Diabetes Technol Ther, 2017, 19(8): 457-462. doi: 10.1089/dia.2017.0028 URL
[6]	Sun B, He F, Gao Y, et al. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes[J]. Endocrine, 2019, 64(3): 536-543. doi: 10.1007/s12020-019-01893-1 URL
[7]	Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes[J]. Diabetes Care, 2015, 38(12): 2354-2369. doi: 10.2337/dc15-1188 URL
[8]	Walker GS, Chen JY, Hopkinson H, et al. Structured education using dose adjustment for normal eating (DAFNE) reduces long-term HbA_1c and HbA_1c variability[J]. Diabet Med, 2018, 35(6): 745-749. doi: 10.1111/dme.13621 URL
[9]	Wadén J, Forsblom C, Thorn LM, et al. A_1c variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes[J]. Diabetes, 2009, 58(11): 2649-2655. doi: 10.2337/db09-0693 URL
[10]	Shen Y, Dai D, Lu J, et al. Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease[J]. Cardiovasc Diabetol, 2020, 19(1): 211. doi: 10.1186/s12933-020-01187-1 pmid: 33302958
[11]	Wan EY, Fung CS, Fong DY, et al. Association of variability in hemoglobin A_1c with cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Complications, 2016, 30(7): 1240-1247. doi: 10.1016/j.jdiacomp.2016.05.024 URL
[12]	Zorena K. Anti-inflammatory therapy in diabetic retinopathy[J]. Mediators Inflamm, 2014, 2014: 947896.
[13]	Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment[J]. Dtsch Arztebl Int, 2010, 107(5): 75-83. doi: 10.3238/arztebl.2010.0075 pmid: 20186318
[14]	Hermann JM, Hammes HP, Rami-Merhar B, et al. HbA_1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients[J]. PLoS One, 2014, 9(3): e91137. doi: 10.1371/journal.pone.0091137 URL
[15]	Rosa LCGFD, Zajdenverg L, Souto DL, et al. HbA_1cvariability and long-term glycemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background[J]. J Diabetes Complications, 2019, 33(9): 610-615. doi: 10.1016/j.jdiacomp.2019.05.022 URL
[16]	Penno G, Solini A, Bonora E, et al. HbA_1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36(8): 2301-2310. doi: 10.2337/dc12-2264 URL
[17]	Foo V, Quah J, Cheung G, et al. HbA_1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics[J]. J Diabetes, 2017, 9(2): 200-207. doi: 10.1111/1753-0407.12403 URL
[18]	Takao T, Suka M, Yanagisawa H, et al. Predictive ability of visit-to-visit variability in HbA_1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes[J]. Diabetes Res Clin Pract, 2017, 128: 15-23. doi: 10.1016/j.diabres.2017.03.027 URL
[19]	胡佳琪, 徐慧君, 刘超, 等. HbA_1c变异性的影响因素及其对2型糖尿病视网膜病变的作用[J]. 中华内分泌代谢杂志, 2020, 36(5): 381-386.
[20]	Ioannou K. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis[J]. Hormones (Athens), 2017, 16(4): 351-361.
[21]	Li L, Jiang XG, Hu JY, et al. The association between interleukin-19 concentration and diabetic nephropathy[J]. BMC Nephrol, 2017, 18(1): 65. doi: 10.1186/s12882-017-0488-7 pmid: 28201997
[22]	Furuichi K, Shimizu M, Hara A, et al. Diabetic nephropathy: a comparison of the clinical and pathological features between the CKD risk classification and the classification of diabetic nephropathy 2014 in Japan[J]. Intern Med, 2018, 57(23): 3345-3350. doi: 10.2169/internalmedicine.1132-18 URL
[23]	Lin CC, Chen CC, Chen FN, et al. Risks of diabetic nephropathy with variation in hemoglobin A_1c and fasting plasma glucose[J]. Am J Med, 2013, 126(11): 1017.
[24]	Yun KJ, Kim HJ, Kim MK, et al. Risk factors for the development and progression of diabetic kidney disease in patients with type 2 diabetes mellitus and advanced diabetic retinopathy[J]. Diabetes Metab J, 2016, 40(6): 473-481. doi: 10.4093/dmj.2016.40.6.473 URL
[25]	Dorajoo SR, Ng JSL, Goh JHF, et al. HbA_1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years[J]. Diabetes Res Clin Pract, 2017, 128: 32-39. doi: 10.1016/j.diabres.2017.02.007 URL
[26]	Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies[J]. Diabetologia, 2000, 43(8): 957-973. pmid: 10990072
[27]	Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J]. Neuron, 2017, 93(6): 1296-1313. doi: S0896-6273(17)30089-2 pmid: 28334605
[28]	Su JB, Zhao LH, Zhang XL, et al. HbA_1c variability and diabetic peripheral neuropathy in type 2 diabetic patients[J]. Cardiovasc Diabetol, 2018, 17(1): 47. doi: 10.1186/s12933-018-0693-0 URL
[29]	Lai YR, Chiu WC, Huang CC, et al. HbA_1c variability is strongly associated with the severity of peripheral neuropathy in patients with type 2 diabetes[J]. Front Neurosci, 2019, 13: 90. doi: 10.3389/fnins.2019.00090 URL
[30]	Cardoso CRL, Leite NC, Moram CBM, et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2018, 17(1): 33. doi: 10.1186/s12933-018-0677-0 pmid: 29477146
[31]	Teliti M, Cogni G, Sacchi L, et al. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients[J]. Diab Vasc Dis Res, 2018, 15(5): 424-432. doi: 10.1177/1479164118780808 URL
[32]	Lai YR, Huang CC, Chiu WC, et al. HbA_1c variability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration[J]. Front Neurosci, 2019, 13: 458. doi: 10.3389/fnins.2019.00458 URL
[33]	Yang Y, Lee EY, Cho JH, et al. Cardiovascular autonomic neuropathy predicts higher HbA_1c variability in subjects with type 2 diabetes mellitus[J]. Diabetes Metab J, 2018, 42(6): 496-512. doi: 10.4093/dmj.2018.0026 URL
[34]	Jang JY, Moon S, Cho S, et al. Visit-to-visit HbA_1c and glucose variability and the risks of macrovascular and microvascular events in the general population[J]. Sci Rep, 2019, 9(1): 1374. doi: 10.1038/s41598-018-37834-7 URL
[35]	Shen Y, Zhou J, Shi L, et al. Association between visit-to-visit HbA_1c variability and the risk of cardiovascular disease in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(1): 125-135. doi: 10.1111/dom.14201 URL
[36]	Sheng CS, Tian J, Miao Y, et al. Prognostic significance of long-term HbA_1c variability for all-cause mortality in the ACCORD trial[J]. Diabetes Care, 2020, 43(6): 1185-1190. doi: 10.2337/dc19-2589 URL

糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙艳, 代丹娇, 陈智伟, 张华清. 卡格列净对早期糖尿病肾病尿白蛋白/肌酐比值和尿足细胞相关蛋白裂隙素的影响[J]. 内科理论与实践, 2021, 16(06): 387-391.
[2]	李淑雨, 沈琳辉,. 2型糖尿病患者参考范围甲状腺激素与糖尿病肾病的相关性分析[J]. 内科理论与实践, 2020, 15(01): 38-44.
[3]	邓琳, 丁怡, 汪萍, 卞炳贤, 沈立松. 尿中性粒细胞明胶酶相关脂质运载蛋白/肌酐比值在2型糖尿病肾损伤的早期诊断及病情评估中的临床应用[J]. 诊断学理论与实践, 2019, 18(1): 61-65.
[4]	闫莉, 刘艳, 周华, 李洁,. 糖尿病视网膜病变的诊治进展[J]. 内科理论与实践, 2019, 14(03): 149-153.
[5]	荣岚, 焦洁茹, 林青, 张永怡,. 胰岛素样生长因子1及半胱氨酸蛋白酶抑制剂C在老年2型糖尿病肾病患者中的变化[J]. 内科理论与实践, 2019, 14(02): 127-130.
[6]	谭姣容, 田冬梅, 杨昕, 张立娟, 王芳, 苏玉霞. 维生素D缺乏与糖尿病患者糖尿病肾病发生率的关系研究：前瞻性3年随访研究[J]. 诊断学理论与实践, 2018, 17(02): 176-180.
[7]	陈彦, 陈刚. 糖尿病肾病的诊断策略[J]. 诊断学理论与实践, 2018, 17(01): 11-18.
[8]	徐丽梨, 王伟铭. 生活方式对糖尿病肾病发生发展的影响[J]. 诊断学理论与实践, 2017, 16(05): 553-556.
[9]	李慧凛, 吴萍, 刘爽, 蒋更如. 可溶性Klotho蛋白抑制高糖诱导的STAT3磷酸化通路减轻肾纤维化[J]. 诊断学理论与实践, 2017, 16(04): 371-376.
[10]	李军辉, 程东生, 王锋, 费杨, 薛勤, 汪年松. 糖尿病肾病患者血脂异常与尿蛋白关系[J]. 上海交通大学学报, 2016, 50(03): 478-482.
[11]	谷巍, 耿建林, 赵正历,. 红景天联合培哚普利治疗糖尿病肾病早期临床观察[J]. 内科理论与实践, 2016, 11(02): 103-104.
[12]	丁怡, 邓琳, 沈立松,. 尿中性粒细胞明胶酶相关脂质运载蛋白在2型糖尿病肾病诊断和评估中的临床应用[J]. 诊断学理论与实践, 2016, 15(01): 61-64.
[13]	顾佩莉, 蒋晓真, 陈蕊华, 汪瑞忠, 顾哲, 周斌, 朱震宏, 邹宇峰, 徐凌燕, 顾桂国,. 血清chemerin、C反应蛋白及白介素6与糖尿病肾病的相关性研究[J]. 内科理论与实践, 2016, 11(01): 33-37.
[14]	谭姣容, 田冬梅, 杨昕, 张立娟, 王芳, 童平,. 维生素D_3水平与2型糖尿病肾病的关系研究[J]. 诊断学理论与实践, 2015, 14(05): 425-428.
[15]	张弘玮, 狄建忠, 于浩泳, 韩晓东, 张频,. 胃旁路术对糖尿病肾病蛋白尿影响的随访研究[J]. 外科理论与实践, 2015, 20(05): 399-402.